

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application: Claims 1-34 have been previously canceled.

Listing of Claims:

1-34 (CANCELED)

35. (PREVIOUSLY PRESENTED) A method for inducing the in vivo production of neurotropic growth factors in a mammal, said method comprising the step of treating a mammal with an effective amount of at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative.

36. (PREVIOUSLY PRESENTED) The method of claim 35 wherein said carbon monoxide dependent guanylyl cyclase modulating purine derivative is 3-(1, 6-dihydro-6-oxo-9H-purin-9-yl)-1-oxo-propyl amino benzoic acid.

37. (PREVIOUSLY PRESENTED) The method of claim 35 wherein said effective amount of said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative produces a treating concentration of at least 1 μ M.

38. (PREVIOUSLY PRESENTED) The method of claim 35 wherein said neurotropic growth factors are selected from the group consisting of nerve growth factor (NGF), fibroblast growth factor-2(FGF-2), and neurotrophin-3 (NT-3).

39. (PREVIOUSLY PRESENTED) The method of claim 37 wherein said mammal is treated by orally administering said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative.

40. (PREVIOUSLY PRESENTED) The method of claim 37 wherein said mammal is treated by injecting said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative.